Lonza Further Extends Collaboration with Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
Die Gewinner des 10. BioRiver Boost! 2023 stehen fest. Den ersten Platz belegte Akribion Genomics aus Zwingenberg. Das U…
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17…
Der führende Energiedienstleister und Industrieparkbetreiber GETEC übernimmt alle Immobilien, infrastrukturbezogenen V…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…
TÜV SÜD Schweiz AG has acquired the process safety laboratory of Lonza Ltd. at its Visp site, Switzerland. By expanding…
Die TÜV SÜD Schweiz AG hat das Labor für Prozesssicherheit der Lonza AG am Standort Visp in der Schweiz übernommen. Durc…
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition w…
Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing…